ConductScience.org, home

Paper39089293

Efficacy and safety of once-weekly semaglutide 2·4 mg versus placebo in people with obesity and prediabetes (STEP 10): a randomised, double-blind, placebo-controlled, multicentre phase 3 trial.

McGowan BM and 9 others. Lancet Diabetes Endocrinol, 2024. Cited by 154 papers, by iCite.

Cite this record

ConductScience Library. Efficacy and safety of once-weekly semaglutide 2·4 mg versus placebo in people with obesity and prediabetes (STEP 10): a randomised, double-blind, placebo-controlled, multicentre phase 3 trial. Papers, record 39089293. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/39089293

Download JSON
Disease
obesity disorder354 drugs
Sources
11 sources
Release
papers-2026-11-12-0.1.0

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
Efficacy and safety of once-weekly semaglutide 2·4 mg versus placebo in people with obesity and prediabetes (STEP 10): a randomised, double-blind, placebo-controlled, multicentre phase 3 trial.
PubMed
Journal
Lancet Diabetes Endocrinol
PubMed
Year
2024
PubMed
Publication types
Journal Article, Randomized Controlled Trial, Clinical Trial, Phase III, Multicenter Study, Research Support, Non-U.S. Gov't
PubMed
Citations, by iCite
154
iCite
Relative citation ratio, by iCite
24.87, provisional
iCite
Revised in PubMed
2026-01-27
PubMed

Authors10

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

OrderAuthorForenameKindORCID iD
1McGowan BMBarbara M
2Bruun JMJens M
3Capehorn MMatt
4Pedersen SDSue D
5Pietiläinen KHKirsi H
6Muniraju HAKHanna Angelene Kudiyanur
7Quiroga MMaria
8Varbo AAnette
9Lau DCWDavid C W
10STEP 10 Study GroupGroup

Source PubMed

Download CSV of authors

Topics15

NLM's MeSH indexing of the paper, its major topics first.

MeSH termMajor
Glucagon-Like PeptidesMajor topic
Hypoglycemic AgentsMajor topic
ObesityMajor topic
Prediabetic StateMajor topic
Adult
Aged
Female
Humans
Male
Middle Aged
Blood Glucose
Double-Blind Method
Treatment Outcome
Weight Loss
Semaglutide

Source PubMed

Download CSV of topics

Trials1

The trials whose ClinicalTrials.gov record lists the paper, and the trial numbers the paper's PubMed record names.

TrialTitleThe trial lists it asNamed in the paper's record
NCT05040971Research Study Looking at How Well Semaglutide Works in People Living With Obesity and PrediabetesResultsYes

Source ClinicalTrials.gov

Download CSV of trials

Comments and corrections1

PubMed's comments and corrections, NLM's own indexing: retractions first, then expressions of concern, errata and updates, and comments last.

KindPMIDTitleIn Papers
Comment in39089292Prediabetes remission in people with obesity.https://conductscience.org/library/papers/39089292

Source PubMed

Download CSV of comments and corrections

Cited by105

The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 154 citations.

PMIDTitleJournalYearIn PapersSource
42941232Weight Regain After Discontinuation of GLP-1 and GIP/GLP-1 Receptor Agonists: A Systematic Review.Metabolites2026https://conductscience.org/library/papers/42941232PubMed
42889937Pharmacologic Treatment of Obesity in Adults: Standards of Care in Overweight and Obesity.Diabetes Obes Cardiometab CARE2026https://conductscience.org/library/papers/42889937PubMed
42824923Predictors of treatment response to semaglutide for weight management.Front Endocrinol (Lausanne)2026https://conductscience.org/library/papers/42824923PubMed
42789525Beyond Prescribing: GLP-1 Care and Obesity Prevention in Primary Care.J Prim Care Community Health2026https://conductscience.org/library/papers/42789525PubMed
42733128Weight Reduction Heterogenicity and Mediators of GLP-1RAs and Dual Agonists for Individuals With Obesity: A Meta-Analysis.Clin Obes2026https://conductscience.org/library/papers/42733128PubMed
42718474Electroacupuncture enables semaglutide dose sparing in type 2 diabetes by boosting drug concentration and suppressing β-cell apoptosis.Front Endocrinol (Lausanne)2026https://conductscience.org/library/papers/42718474PubMed
42673571Weight Regain Trajectories After Discontinuation of Semaglutide or Tirzepatide: A Reconstructed Aggregate-Data Bayesian Longitudinal Meta-Analysis.Endocrinol Diabetes Metab2026https://conductscience.org/library/papers/42673571PubMed
42658458Prediabetes: diagnostic aspects, clinical features, and emerging therapeutic opportunities, with a focus on Vitamin D.J Endocrinol Invest2026https://conductscience.org/library/papers/42658458PubMed
42603240Effect of tirzepatide and semaglutide on blood pressure: A systematic review and meta-analysis.Endocrine2026https://conductscience.org/library/papers/42603240PubMed
42575984Type 2 diabetes prevention across the life course.Nat Med2026https://conductscience.org/library/papers/42575984PubMed
42560457Analysis of the efficacy and safety of liraglutide, semaglutide, and tirzepatide for the treatment of overweight and obesity: a systematic review and network meta-analysis.J Endocrinol Invest2026https://conductscience.org/library/papers/42560457PubMed
42503575
A Cost-Effectiveness Model of Semaglutide 2.4 mg, Resmetirom 80 mg, and Resmetirom 100 mg Versus Standard of Care for the Treatment of Metabolic Dysfunction-Associated Steatohepatitis in the United States.
Pharmacoeconomics2026https://conductscience.org/library/papers/42503575PubMed
42482018Association of creatinine to body weight ratio with glycemic progression and remission in Chinese adults with prediabetes: a large-scale retrospective cohort study.BMC Endocr Disord2026https://conductscience.org/library/papers/42482018PubMed
42477297EndoBridge 2025: pearls and highlights.Hormones (Athens)2026https://conductscience.org/library/papers/42477297PubMed
42427356A Review of Lifestyle Interventions Provided as an Adjunct to Obesity Management Medications.Obes Sci Pract2026https://conductscience.org/library/papers/42427356PubMed
42388883Beyond weight loss: predictors of treatment satisfaction and patient-reported outcomes in incretin-based therapies. A cross-sectional study.Front Endocrinol (Lausanne)2026https://conductscience.org/library/papers/42388883PubMed
42381999Semaglutide alleviates osteoarthritis independent of weight loss via GLP-1R-mediated activation of autophagy through AKT/mTOR inhibition.J Orthop Translat2026https://conductscience.org/library/papers/42381999PubMed
42347027Proteomic Signatures of 3-Year Progression From Impaired Fasting Glucose to Diabetes: The Atherosclerosis Risk in Communities (ARIC) Study.Diabetes Care2026https://conductscience.org/library/papers/42347027PubMed
42316327Cardiovascular outcomes of semaglutide and tirzepatide in type 2 diabetes mellitus and obesity: a systematic review and meta-analysis.Diabetol Metab Syndr2026https://conductscience.org/library/papers/42316327PubMed
42280424GLP-1RA- and Incretin-Based Therapies Within Lifestyle Interventions for Adults with Overweight or Obesity: A Systematic Review and Meta-Analysis.Nutrients2026https://conductscience.org/library/papers/42280424PubMed

See all 105 cited byDownload CSV of cited by

Genes1

The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.

GeneNCBI Gene IDLinked byIn Genes
GLP1R2740PubTator's text mininghttps://conductscience.org/library/genes/2740

Source NCBI Gene

Download CSV of genes

Drugs1

The drugs whose trials, in the Pipelines release, list the paper.

DrugChEMBL IDThe trials list it asTrialsIn Drugs and targets
SEMAGLUTIDECHEMBL2108724Results1https://conductscience.org/library/drugs/CHEMBL2108724

Source ChEMBL

Download CSV of drugs

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

None in this release

  • Grants
  • References
  • Data

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/39089293

GET https://conductscience.org/api/papers/v1/39089293/cited_by?page=2